Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24113153 | 1.00 | L3MBTL1 (0.37) | L3MBTL1CCR2CTSLCTSBCTSS | |
| SCHEMBL22758588 | 1.00 | L3MBTL1 (0.37) | L3MBTL1CCR2CTSLCTSBCTSS | |
| SCHEMBL26601377 | 1.00 | L3MBTL1 (0.37) | L3MBTL1CCR2CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL26601380 | 0.99 | L3MBTL1 (0.36) | L3MBTL1CCR2CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL26601364 | 0.99 | L3MBTL1 (0.36) | L3MBTL1CCR2CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL30377284 | 0.99 | L3MBTL1 (0.36) | L3MBTL1CCR2CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL30623995 | 0.92 | POLB (0.36) | L3MBTL1CCR2HSD17B10 | |
| SCHEMBL14838021 | 0.91 | CTSL (0.38) | CTSLCTSB | |
| SCHEMBL15985641 | 0.91 | CTSL (0.38) | CTSLCTSB | |
| SCHEMBL23754143 | 0.91 | CTSL (0.38) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | L3MBTL1 605/4885CCR2 1005/4885CTSL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.